Back to Discover

Vor Biopharma Inc.

VOR · Biotech · Nasdaq · As of 10 Sep 2026
55AIR SCORE
  • FundamentalsNot enough data yet
  • ValueNot enough data yet
  • News flowBalanced
  • MomentumBalanced
  • SafetyBalanced

Overall confidence 41/100 — few inputs available yet

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.

Discovery Gap: Very high (64/100) · Gap confidence 66/100Documented progress is running well ahead of market attention.

This month at a glance

AIR Score™ change: -1Slipped -1 on softer inputs.
Cycle window9 Sep 202610 Sep 2026
Momentum-1Weighed on the latest score.

Evidence timeline

  1. [8-K 5.02] Vor Biopharma Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
    Jul 6, 2026 · 8-K
  2. [8-K 3.02] Vor Biopharma Inc. — Unregistered Sales of Equity SecuritiesSEC · SEC EDGAR
    Mar 26, 2026 · 8-K
  3. [8-K 1.01] Vor Biopharma Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
    Mar 26, 2026 · 8-K
  4. [8-K 2.02] Vor Biopharma Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
    Jan 12, 2026 · 8-K
  5. [8-K 5.02] Vor Biopharma Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
    Dec 31, 2025 · 8-K
  6. [8-K 3.02] Vor Biopharma Inc. — Unregistered Sales of Equity SecuritiesSEC · SEC EDGAR
    Dec 15, 2025 · 8-K
  7. [8-K 1.01] Vor Biopharma Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
    Dec 15, 2025 · 8-K
  8. [8-K 5.02] Vor Biopharma Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
    Dec 15, 2025 · 8-K
  9. [8-K 5.02] Vor Biopharma Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
    Dec 5, 2025 · 8-K
  10. [8-K 8.01] Vor Biopharma Inc. — Other EventsSEC · SEC EDGAR
    Nov 10, 2025 · 8-K
  11. [8-K 5.02] Vor Biopharma Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
    Nov 2, 2025 · 8-K
  12. [8-K 3.03] Vor Biopharma Inc. — Material Modification to Rights of Security HoldersSEC · SEC EDGAR
    Sep 17, 2025 · 8-K

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or attention arriving — which closes the gap by design would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.